Cargando…
2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
BACKGROUND: In Ontario, Canada, PCV13 is covered for immunocompromised (IC) adults over 50y. PCV13 programs are thought not to be cost-effective in other adults because it is assumed that herd immunity from pediatric vaccination programs (PCV7 since 2005; PCV13 since 2010) will reduce PCV13 disease...
Autores principales: | McGeer, Allison, Plevneshi, Agron, Green, Karen, Coleman, Brenda, Nayani, Sarah, Rudnick, Wallis, Simor, Andrew, Gold, Wayne, Katz, Kevin, Kitai, Ian, Johnstone, Jennie, Martin, Irene, Muller, Matthew P, Richardson, David, Sarabia, Alicia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809886/ http://dx.doi.org/10.1093/ofid/ofz360.2393 |
Ejemplares similares
-
1426. Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in Ontario, Canada
por: Nayani, Sarah, et al.
Publicado: (2018) -
Changing Epidemiology of Invasive Pneumococcal Disease due to Conjugate Vaccine Serotypes in Toronto, Canada After Introduction of a Routine Pediatric PCV13 Program
por: Mcgeer, Allison, et al.
Publicado: (2017) -
2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
por: Fear, Thomas, et al.
Publicado: (2018) -
295. Is Herd Immunity from Pneumococcal Conjugate Vaccines Changing the Clinical Features of Invasive Pneumococcal Disease in Adults?
por: McGeer, Allison, et al.
Publicado: (2020) -
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)